Accurate Education - Nutraceuticals to Reduce the Driving Forces of Chronic Pain (Part 2)

Nutraceuticals:

Nutraceuticals to Reduce the Driving Forces of Chronic Pain (Part 2)

This section (Part 2) presents a synthesis of research to identify the nutraceuticals with the best evidence of efficacy for the following conditions that are driving forcex in the development and maintenance of chronic pain:

See:

Nutraceuticals to Reduce the Driving Forces of Chronic Pain (Part 1)

See also:

Central Sensitization (CS)

Patient Guides for Nutraceuticals 11-16 (Part 2):

See also:

Patient Guides for Nutraceuticals 1-10 (Part 1):

Nutraceuticals 1-10 (Part 1):

Nutraceutical Patient Guides:

Nutraceuticals 11-16 (Part 2):

Key to Links:

Grey text – handout
Red text – another page on this website
Blue text – Journal publication

Definitions and Terms Related to Pain

PART 2 (#11-16)

Summary

Updated: March 2026

This comprehensive treatise synthesizes current evidence for nutraceutical interventions targeting the pathophysiological mechanisms underlying chronic pain, including systemic inflammation, oxidative stress, neuroinflammation and mitochondrial dysfunction as well as central sensitization.

The following analysis evaluates the highest-quality current evidence for each compound, including recommendations for integrating these agents into multimodal pain management strategies.

Nutraceuticals to Reduce the Driving Forces of Chronic Pain:

Part 2 – Nutraceuticals 11-16 and Summary

(CONTINUATION FROM NUTRACEUTICAL 10)

11. NAD+ PRECURSORS (Nicotinamide Riboside/NMN)

Level of Evidence

Grade B-C: Strong preclinical evidence; limited but emerging clinical evidence; moderate-quality evidence for neuropathy[2][3][4][5]

Primary Indications

Chemotherapy-induced peripheral neuropathy (strongest preclinical evidence)
Diabetic peripheral neuropathy
Trigeminal neuropathic pain
Age-related mitochondrial dysfunction5. Chronic fatigue syndrome (in combination with CoQ10)

Mechanisms of Action

NAD+ repletion: Restores cellular NAD+ levels depleted by aging, metabolic stress, and nerve injury[6][7]
Mitochondrial function enhancement: Essential cofactor for oxidative phosphorylation; improves ATP production
SIRT1 activation: Enhances mitochondrial fitness and suppresses pain-related gene expression[5]
Neuroprotection: Protects against intraepidermal nerve fiber loss[2][4]
Anti-inflammatory effects: Suppresses neuroinflammation via Sirt1-mediated mechanisms[5]
Axonal protection: Preserves nerve structure and function in neuropathy models[3]

Recommended Dosing

Nicotinamide riboside (NR): 250-500 mg twice daily (500-1000 mg/day total)
Nicotinamide mononucleotide (NMN): 250-500 mg/day
Duration: Minimum 8-12 weeks
Timing: Can be taken with or without food; morning dosing may be preferred

Formulation Considerations

NR (Niagen®): Most studied form; FDA GRAS status
NMN: Emerging evidence; may have different tissue distribution
Both forms effectively raise NAD+ levels in humans[6][7]

Estimated Cost

Nicotinamide riboside: $40-80/month
NMN: $50-100/month

Safety Profile – Good safety

Well-tolerated in human studies at doses up to 2000 mg/day[6][7]– Mild GI upset (rare)
Flushing not observed (unlike niacin)
No serious adverse events in clinical trials
Long-term safety data still accumulating

Synergistic Combinations

1CoQ10: Enhanced mitochondrial function
2Alpha-lipoic acid: Complementary antioxidant effects
3Resveratrol: Synergistic SIRT1 activation

Clinical Pearls

Preclinical evidence shows NR prevents and reverses paclitaxel-induced periphera neuropathy[2][4]
NR protects against diabetic neuropathy independent of glycemic control[3]
Analgesic effects depend on Sirt1 activation and suppression of pain genes[5].
Human clinical trials for pain are limited; efficacy may be lower than preclinical predictions[7]
May enhance tumor suppression when combined with chemotherapy (not antagonistic)[2]

—

12. VITAMIN D3 (Cholecalciferol)

Level of Evidence

Grade B-C: Multiple systematic reviews and meta-analyses with mixed results; moderate-quality evidence[8][9][10][11][12]

Primary Indications

1Chronic widespread pain/fibromyalgia (modest evidence)
Chronic musculoskeletal pain
Vitamin D-deficient patients with chronic pain
Neuropathic pain (preclinical evidence)
Migraine (limited evidence)

Mechanisms of Action

Opioid signaling modulation: Upregulates genes associated with opioid signaling in cerebrum[13]
Neuroinflammation reduction: Decreases pro-inflammatory cytokine production
Nociception modulation: Regulates expression of nociception and allodynia-related genes[13]
Calcium homeostasis: Essential for neuromuscular function
Immunomodulation: Regulates immune cell function and inflammatory responses
Axonal guidance: Modulates genes involved in nerve regeneration[13]

Recommended Dosing

Deficiency correction: 50,000 IU weekly × 8 weeks, then maintenance
Maintenance: 1000-4000 IU/day (25-100 mcg/day)
Target serum 25(OH)D: 40-60 ng/mL (100-150 nmol/L)
Duration: Ongoing; benefits may require 3-6 months
Timing: Take with fat-containing meal for optimal absorption

Formulation Considerations

Vitamin D3 (cholecalciferol) preferred over D2 (ergocalciferol)
Oil-based softgels may improve absorption
High-dose monthly regimens (60,000 IU) studied but may be less effective than daily dosing[9]

Estimated Cost

Standard vitamin D3: $5-15/month
High-potency formulations: $10-25/month

Safety Profile – Excellent safety at recommended doses

Well-tolerated at doses up to 4000 IU/day
Hypercalcemia risk at very high doses (>10,000 IU/day chronically)
Monitor serum 25(OH)D and calcium in high-dose regimens
Caution in granulomatous diseases, primary hyperparathyroidism

Synergistic Combinations

Omega-3 fatty acids: Enhanced immunomodulation
Magnesium: Required for vitamin D metabolism
Vitamin K2: Improved calcium utilization

Clinical Pearls

Cochrane review found no consistent pattern of benefit across chronic pain conditions[8]
Meta-analysis showed significant benefit in patients with pre-existing pain (mean change from baseline)[10]
Large D-Health Trial (60,000 IU monthly) showed negligible effect on pain[9]
Vitamin D-deficient patients (<50 nmol/L) may benefit more from supplementation[11]
Chronic widespread pain/fibromyalgia may show modest improvement with supplementation[12]
Preclinical evidence suggests vitamin D modulates opioid signaling pathways[13]
Check baseline 25(OH)D levels; correct deficiency before expecting analgesic benefit

—

13. MELATONIN

Level of Evidence

Grade B: Multiple meta-analyses and RCTs; moderate-quality evidence for chronic pain[14][15] [16][17][18][19]

Primary Indications

Fibromyalgia (strongest evidence)
Chronic pain with sleep disturbance
Migraine prophylaxis
Irritable bowel syndrome-related pain
Perioperative pain (acute setting)

Mechanisms of Action

Melatonin receptor activation: MT1 and MT2 receptor-mediated analgesia
Opioid system modulation: Interacts with μ-opioid receptors[17]
GABAergic enhancement: Potentiates GABA-B receptor activity[17]
Anti-inflammatory effects: Reduces pro-inflammatory cytokines
Antioxidant activity: Direct free radical scavenging
Sleep improvement: Indirect pain reduction via improved sleep quality[18]
BDNF modulation: Reduces brain-derived neurotrophic factor levels associated with pain[16]

Recommended Dosing

Chronic pain: 3-10 mg at bedtime
Fibromyalgia: 3-5 mg at bedtime (often combined with fluoxetine)[19]
Modified-release formulations: 2 mg (Circadin™) at bedtime[18]
Duration: Minimum 8 weeks; benefits may be transient (peak at 3 weeks)[18]
Timing: 30-60 minutes before bedtime

Formulation Considerations

Immediate-release: Faster onset; may be better for sleep initiation
Modified-release (Circadin™): Sustained levels; studied for chronic pain[18]– Sublingual formulations: Faster absorption

Estimated Cost

Standard melatonin: $5-15/month
Modified-release formulations: $15-30/month

Safety Profile – Excellent safety

Well-tolerated at doses up to 10 mg/day
Drowsiness, headache (uncommon)
No serious adverse events in clinical trials[18]
No tolerance development
Safe for long-term use
Caution with sedatives, anticoagulants

Synergistic Combinations

Fluoxetine: Enhanced efficacy in fibromyalgia (combination superior to either alone)[19]
Magnesium: Complementary sleep and pain effects
Omega-3 fatty acids: Additive anti-inflammatory effects

Clinical Pearls

Meta-analysis shows significant reduction in chronic pain (SMD -0.65)[14]
Combination with fluoxetine more effective than either alone for fibromyalgia[19]
Benefits may be transient; improvements seen at 3 weeks may not persist at 6 weeks[18]
Particularly useful when sleep disturbance contributes to pain[17].
Favorable safety profile makes it suitable for long-term adjunctive use[18]
May reduce analgesic requirements and BDNF levels[16]

14. SULFORAPHANE

Level of Evidence

Grade C: Strong preclinical evidence; limited clinical trials in pain; emerging evidence[20][21] [22][23][24]

Primary Indications

Inflammatory pain (preclinical evidence)
Neuropathic pain (emerging evidence)
Neuroinflammation-driven chronic pain
Central sensitization states
Oxidative stress-related pain conditions

Mechanisms of Action

1Nrf2 activation: Potent inducer of nuclear factor erythroid 2-related factor 2; upregulatescytoprotective enzymes (HO-1, NQO1)[20][21][22]
Neuroinflammation suppression: Inhibits microglial activation and NF-κB signaling[25]
Antioxidant enzyme induction: Enhances endogenous antioxidant capacity
MAPK pathway inhibition: Reduces inflammatory signaling[21]
NOS2 suppression: Decreases inducible nitric oxide synthase expression[21]
MOR upregulation: Increases μ-opioid receptor expression; enhances morphine efficacy[21]

Recommended Dosing

Sulforaphane: 10-50 mg/day (equivalent to 100-400 mg broccoli seed extract)
Broccoli sprout extract: 100-400 mg/day (standardized to sulforaphane content)
Glucoraphanin (precursor): 30-100 mg/day (requires myrosinase for conversion)
Duration: Minimum 4-8 weeks
Timing: Take with meals; myrosinase-containing foods may enhance conversion

Formulation Considerations

Stabilized sulforaphane preferred over glucoraphanin alone
Myrosinase-active formulations enhance bioavailability
Broccoli sprout extracts: Ensure standardization to sulforaphane content
Fresh broccoli sprouts: Natural source but variable content

Estimated Cost

Broccoli sprout extract: $20-40/month
Stabilized sulforaphane: $30-60/month

Safety Profile – Good safety

Well-tolerated in clinical studies
GI upset at high doses (rare)
Thyroid effects at very high doses (theoretical; not clinically significant at recommended doses)
No serious adverse events reported

Synergistic Combinations

Morphine: Sulforaphane enhances morphine analgesia and reduces tolerance[21]
Curcumin: Complementary Nrf2 and NF-κB modulation
Alpha-lipoic acid: Additive antioxidant effects
Resveratrol: Synergistic Nrf2 activation

Clinical Pearls

Potent Nrf2 activator with extensive preclinical evidence for neuroprotection[20][22][24]
Enhances morphine analgesia and may reduce opioid tolerance[21]
Inhibits inflammatory pain via multiple mechanisms (MAPK, NF-κB, NOS2)[21].
Clinical trials in pain are limited; most evidence from preclinical models[22]– Low doses consistently show beneficial effects; higher doses may be cytotoxic[24]
May be particularly useful for neuroinflammation-driven chronic pain

15. QUERCETIN

Level of Evidence

Grade B-C: Extensive preclinical evidence; limited clinical trials in pain; moderate-quality evidence[26][27][28][29][30][31]

Primary Indications

Osteoarthritis (emerging evidence)
Inflammatory pain
Rheumatoid arthritis
Neuropathic pain (preclinical evidence)
Cancer pain (preclinical evidence)

Mechanisms of Action

NF-κB inhibition: Suppresses pro-inflammatory cytokine production (IL-1β, IL-6, TNF-α) [28][29]
COX-2 inhibition: Reduces prostaglandin synthesis[31]
Antioxidant activity: Direct free radical scavenging; reduces ROS[28]
SIRT1 activation: Enhances mitochondrial biogenesis via PGC-1α pathway[30]
Macrophage polarization: Promotes M2 (anti-inflammatory) phenotype[29]
cGAS/STING pathway modulation: Reduces VEGFA-mediated nociception in osteoarthritis[27]
GABAergic and opioidergic modulation: Contributes to analgesic effects[26]

Recommended Dosing

Standard quercetin: 500-1000 mg/day in divided doses- Quercetin phytosome (enhanced absorption): 250-500 mg/day
Co-ultramicronized with PEA: 350-700 mg twice daily
Duration: Minimum 8-12 weeks
Timing: Take with meals containing fat

Formulation Considerations

Poor native bioavailability; enhanced formulations recommended
Quercetin phytosome: Improved absorption
Co-ultramicronized with PEA: Synergistic effects; enhanced CNS penetration
Quercetin dihydrate: Standard form

Estimated Cost

Standard quercetin: $15-30/month
Enhanced bioavailability formulations: $25-50/month
Co-ultramicronized with PEA: $50-80/month

Safety Profile – Good safety

Well-tolerated at doses up to 1000 mg/day
GI upset at high doses (uncommon)
Theoretical interaction with certain medications (CYP3A4 substrate)
No serious adverse events in clinical studies

Synergistic Combinations

PEA (co-ultramicronized): Enhanced anti-inflammatory and analgesic effects
Resveratrol: Complementary antioxidant and anti-inflammatory activity
Curcumin: Additive NF-κB inhibition
Bromelain: Enhanced absorption and anti-inflammatory effects

Clinical Pearls

Emerging evidence for analgesic effects via multiple mechanisms[26]
Preclinical studies show potent effects in inflammatory, neuropathic, and cancer pain models[26]
Alleviates osteoarthritis by inhibiting inflammation, apoptosis, and promoting M2 macrophage polarization[29]
SIRT1 activation contributes to anti-arthritic effects[30]
Bioavailability is a significant challenge; enhanced formulations recommended.
Co-ultramicronized with PEA may provide synergistic benefits
Meta-analysis of preclinical studies shows significant improvement in OARSI cartilage scores[32]

—

16. TAURINE

Level of Evidence

Grade B-C: Moderate preclinical evidence; limited clinical trials; emerging evidence for diabetic neuropathy[33][34][35][36][37][2]

Primary Indications

Diabetic peripheral neuropathy (strongest evidence)
Neuropathic pain
Chronic pain with opioid tolerance
Hyperalgesia states
Neuromuscular pain

Mechanisms of Action

Glycine receptor activation: Mediates spinal antinociceptive effects[35]2. Calcium signaling modulation: Normalizes abnormal Ca²⁺ homeostasis in sensory neurons[36]
Schwann cell protection: Prevents apoptosis via NGF/Akt/GSK3β pathway[33]
Axonal protection: Ameliorates axonal damage via PI3K/Akt/mTOR pathway[34]
Muscarinic receptor involvement: Contributes to peripheral analgesic effects[5]
NMDA receptor modulation: Partial inhibition reduces central sensitization[2]
Osmolyte function: Maintains cellular volume and function under stress
Nrf2/HO-1 activation: Reduces oxidative stress and neuroinflammation[37]

Recommended Dosing

Chronic pain: 1000-3000 mg/day in divided doses
Diabetic neuropathy: 1500-3000 mg/day (0.5-2% in drinking water equivalent in animal studies)[33][34]
Duration: Minimum 6-12 weeks
Timing: Can be taken with or without food; divided dosing preferred

Formulation Considerations

Standard taurine powder or capsules widely available
Often included in energy drinks (lower doses)
Pharmaceutical-grade preferred for therapeutic use

Estimated Cost

Standard taurine: $10-25/month

Safety Profile – Excellent safety

Well-tolerated at doses up to 6000 mg/day
No serious adverse events reported
Endogenous amino acid with established safety profile- May enhance effects of sedatives (theoretical)

Synergistic Combinations

Morphine: Reduces morphine tolerance and dependence[5]
Alpha-lipoic acid: Complementary neuroprotective effects
B-complex vitamins: Enhanced nerve function

Clinical Pearls

Intrathecal taurine attenuates neuropathic pain via glycine receptor activation[35]
Protects against myelin damage and axonal injury in diabetic neuropathy[33][34]
Normalizes abnormal calcium signaling in sensory neurons, reducing hyperexcitability[36]
May reduce opioid tolerance and dependence when used in combination[5]
Taurine deficiency in diabetes may predispose to nerve hyperexcitability and pain[36]
Ameliorates neuropathy via NF-κB suppression and Nrf2/HO-1 activation[37]
Clinical trials specifically for pain are limited; most evidence from diabetic neuropathy models

—

SUMMARY AND CLINICAL INTEGRATION

Evidence Hierarchy for Chronic Pain Nutraceuticals

Based on evidence reviewed 3/22/26:

Grade A (High-quality evidence – mixed conclusions):

Palmitoylethanolamide (PEA)
Omega-3 fatty acids (EPA/DHA)

Grade A-B (Moderate-to-high quality evidence):

Curcumin: An umbrella meta-analysis of 11 meta-analyses confirmed significant reductions in VAS and WOMAC scores for osteoarthritis. VA/DoD guidelines note positive effects compared to placebo.[5][6]
Boswellia serrata: A Cochrane review found high-quality evidence for enriched Boswellia extract improving pain and function in OA, with NNTB of 2-4. Multiple recent RCTs confirm efficacy.[9][10][11]
Omega-3 fatty acids: A 2025 meta-analysis of 41 RCTs showed moderate pain reduction (SMD -0.55), but the large VITAL trial (n=25,871) found no effect on pain prevalence or severity with standard dosing. Benefits appear condition-specific (rheumatoid arthritis, migraine) rather than universal.[3][4]

Grade B (Moderate-quality evidence):

Alpha-lipoic acid: A 2024 Cochrane review concluded ALA “probably has little or no effect on neuropathy symptoms” at 6 months (moderate-certainty evidence). The SYDNEY 2 trial showed benefit at 600 mg/day, but long-term evidence is limited.[7][8]
CoQ10: Evidence is limited primarily to fibromyalgia, with small studies (n=20-22) showing benefit. Should remain Grade B or possibly B-C.[12][13]
Magnesium (for migraine): AAN guidelines classify it as “probably effective” (Level B), and umbrella reviews confirm strong GRADE evidence for reducing migraine frequency/intensity.[14][15]
Melatonin: Evidence is mixed. A 2020 meta-analysis showed benefit for chronic pain (SMD -0.65), but a 2025 RCT found no benefit for neuropathic pain. Grade B-C may be more appropriate.[16][17]
Palmitoylethanolamide (PEA): While meta-analyses show efficacy (SMD -0.9 to -1.16 for pain reduction), a 2022 Cochrane-style systematic review noted high heterogeneity (I² = 99%) and publication bias, with only two high-quality RCTs available. The evidence is promising but not yet “high-quality.”[1][2]
Acetyl-L-carnitine: A Cochrane review found “very uncertain” evidence for pain reduction in DPN, though a 2024 phase 3 trial in China showed significant improvement in neuropathy scores.[18][19]

Grade B-C (Emerging evidence):

NAD+ precursors
Vitamin D3
Quercetin
N-acetyl cysteine
Resveratrol
Sulforaphane
Taurine

Based on evidence reviewed 3/22/26:

Hierarchy:

Grade	Nutraceuticals	Rationale	References
A-B (Moderate-to-High)	Curcumin (bioavailable forms), Boswellia serrata, Magnesium (migraine)	Multiple meta-analyses, guideline support	[1], [2], [3], [4], [5]
B (Moderate)	PEA, Omega-3 (condition-specific), Alpha-lipoic acid (600 mg/day), Acetyl-L-carnitine	Positive meta-analyses but heterogeneity, conflicting large trials	[6], [7], [8], [9], [10], [11]
B-C (Limited/Emerging)	CoQ10, Melatonin, Vitamin D3, NAD+ precursors, Quercetin, Resveratrol, N-acetyl cysteine, Sulforaphane, Taurine	Small studies, mixed results, or limited human data	[12], [13], [14], [15]

References

Meta-Analysis of Palmitoylethanolamide in Pain Management: Addressing Literature Gaps and Enhancing Understanding. Viña I, López-Moreno M. Nutrition Reviews. 2025;83(7):e1604-e1618. doi:10.1093/nutrit/nuae203.
Effects of Palmitoylethanolamide (PEA) on Nociceptive, Musculoskeletal and Neuropathic Pain: Systematic Review and Meta-Analysis of Clinical Evidence. Scuteri D, Guida F, Boccella S, et al. Pharmaceutics. 2022;14(8):1672. doi:10.3390/pharmaceutics14081672.
Effects of Omega-3 Fatty Acids on Chronic Pain: A Systematic Review and Meta-Analysis. Xie L, Wang X, Chu J, et al. Frontiers in Medicine. 2025;12:1654661. doi:10.3389/fmed.2025.1654661.
The Effect of Vitamin D and Omega-3 Fatty Acid Supplementation on Pain Prevalence and Severity in Older Adults: A Large-Scale Ancillary Study of the VITamin D and OmegA-3 triaL (VITAL). Soens MA, Sesso HD, Manson JE, et al. Pain. 2024;165(3):635-643. doi:10.1097/j.pain.0000000000003044.
The Efficacy of Curcumin in Relieving Osteoarthritis: A Meta-Analysis of Meta-Analyses. Bideshki MV, Jourabchi-Ghadim N, Radkhah N, et al. Phytotherapy Research : PTR. 2024;38(6):2875-2891. doi:10.1002/ptr.8153.
The Non-Surgical Management of Hip & Knee Osteoarthritis (OA) (2020). Matthew Bair MD MS, John Cody MD, Jess Edison MD, et al. Department of Veterans Affairs.
Alpha-Lipoic Acid for Diabetic Peripheral Neuropathy. Baicus C, Purcarea A, von Elm E, Delcea C, Furtunescu FL. The Cochrane Database of Systematic Reviews. 2024;1:CD012967. doi:10.1002/14651858.CD012967.pub2.
Oral Treatment With Alpha-Lipoic Acid Improves Symptomatic Diabetic Polyneuropathy: The SYDNEY 2 Trial. Ziegler D, Ametov A, Barinov A, et al. Diabetes Care. 2006;29(11):2365-70. doi:10.2337/dc06-1216.
Oral Herbal Therapies for Treating Osteoarthritis. Cameron M, Chrubasik S. The Cochrane Database of Systematic Reviews. 2014;(5):CD002947. doi:10.1002/14651858.CD002947.pub2.
Clinical Benefits of Boswellia Serrata (BOSMAX®) in Early Knee Osteoarthritis: A Randomized, Placebo-Controlled, Double-Blind Study. Jayaram M, Kim J, Baek KS, et al. Journal of Medicinal Food. 2025;. doi:10.1177/1096620X251392467.
A Standardized Boswellia Serrata Extract Shows Improvements in Knee Osteoarthritis Within Five Days-a Double-Blind, Randomized, Three-Arm, Parallel-Group, Multi-Center, Placebo-Controlled Trial. Majeed A, Majeed S, Satish G, et al. Frontiers in Pharmacology. 2024;15:1428440. doi:10.3389/fphar.2024.1428440.
Can Coenzyme Q10 Improve Clinical and Molecular Parameters in Fibromyalgia?. Cordero MD, Alcocer-Gómez E, de Miguel M, et al. Antioxidants & Redox Signaling. 2013;19(12):1356-61. doi:10.1089/ars.2013.5260.
Role for a Water-Soluble Form of CoQ10 in Female Subjects Affected by Fibromyalgia. A Preliminary Study. Di Pierro F, Rossi A, Consensi A, Giacomelli C, Bazzichi L. Clinical and Experimental Rheumatology. 2017 May-Jun;35 Suppl 105(3):20-27.
Evidence-Based Guideline Update: NSAIDs and Other Complementary Treatments for Episodic Migraine Prevention in Adults: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Holland S, Silberstein SD, Freitag F, et al. Neurology. 2012;78(17):1346-53. doi:10.1212/WNL.0b013e3182535d0c.
Magnesium and Health Outcomes: An Umbrella Review of Systematic Reviews and Meta-Analyses of Observational and Intervention Studies. Veronese N, Demurtas J, Pesolillo G, et al. European Journal of Nutrition. 2020;59(1):263-272. doi:10.1007/s00394-019-01905-w.
Analgesic Efficacy of Melatonin: A Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled Trials. Oh SN, Myung SK, Jho HJ. Journal of Clinical Medicine. 2020;9(5):E1553. doi:10.3390/jcm9051553.
Melatonin for Neuropathic Pain: A Double-Blind, Placebo-Controlled, Randomized, Crossover Trial. Gilron I, Elkerdawy H, Tu D, et al. Pain. 2025;:00006396-990000000-00905. doi:10.1097/j.pain.0000000000003651.
Acetyl-L-Carnitine for the Treatment of Diabetic Peripheral Neuropathy. Rolim LC, da Silva EM, Flumignan RL, Abreu MM, Dib SA. The Cochrane Database of Systematic Reviews. 2019;6:CD011265. doi:10.1002/14651858.CD011265.pub2.
Acetyllevocarnitine Hydrochloride for the Treatment of Diabetic Peripheral Neuropathy: A Phase 3 Randomized Clinical Trial in China. Guo L, Pan Q, Cheng Z, et al. Diabetes. 2024;73(5):797-805. doi:10.2337/db23-0377.
Acetyl-L-Carnitine in Painful Peripheral Neuropathy: A Systematic Review. Di Stefano G, Di Lionardo A, Galosi E, Truini A, Cruccu G. Journal of Pain Research. 2019;12:1341-1351. doi:10.2147/JPR.S190231.

Suggested Combination Protocols by Pain Type

Neuropathic Pain:

First-line: Alpha-lipoic acid (600 mg/day) + Acetyl-L-carnitine (2000-3000 mg/day)
Add: PEA (ultramicronized, 600 mg BID) + Omega-3 (1-1.35 g EPA+DHA/day)
Consider: NAD+ precursors (NR 500 mg/day), Taurine (1500-3000 mg/day)

Inflammatory/Osteoarthritis Pain:

First-line: Curcumin (enhanced bioavailability, 500-1000 mg/day) + Boswellia (100-400 mg standardized extract/day)
Add: Omega-3 (1-1.35 g EPA+DHA/day) + Quercetin (500-1000 mg/day)- Consider: Resveratrol (250-500 mg/day)

Fibromyalgia/Central Sensitization:

First-line: PEA (ultramicronized, 600 mg BID) + CoQ10 (300 mg/day)
Add: Magnesium (400-600 mg/day) + Melatonin (3-5 mg at bedtime)
Consider: Omega-3, Vitamin D (if deficient)

Migraine Prophylaxis:

First-line: Magnesium (400-600 mg/day) + CoQ10 (300 mg/day)
Add: Omega-3 (1-1.35 g EPA+DHA/day) + Melatonin (3 mg at bedtime)
Consider: Riboflavin (B2, 400 mg/day)

Chemotherapy-Induced Neuropathy:

First-line: Alpha-lipoic acid (600-1200 mg/day) + Acetyl-L-carnitine (2000-3000 mg/day)
Add: NAD+ precursors (NR 500-1000 mg/day)
Consider: PEA, Omega-3

—

General Principles for Clinical Integration

Start with one or two agents; add sequentially to assess individual response
Allow adequate time for therapeutic effect (typically 8-12 weeks minimum)
Use enhanced bioavailability formulations:

1. Curcumin
2. PEA
3. Quercetin,
4. Resveratrol

Consider underlying pathophysiology when selecting agents:

1. Neuroinflammation → Curcumin, PEA, Sulforaphane
2. Oxidative Stress → Alpha-lipoic acid, NAC, Resveratrol
3. Mitochondrial Dysfunction → CoQ10, NAD+ precursors, Alpha-lipoic acid-
4. Central Sensitization → PEA, Omega-3, Magnesium

Combine agents with complementary mechanisms for synergistic effects

—

References

Resveratrol: Harnessing Nature’s Potential for Chronic Pain Relief. Wu H, Wu JY, Gao SJ, et al. Aging and Disease. 2025;:AD.2025.0530. doi:10.14336/AD.2025.0530.
Nicotinamide Riboside Relieves Paclitaxel-Induced Peripheral Neuropathy and Enhances Suppression of Tumor Growth in Tumor-Bearing Rats. Hamity MV, White SR, Blum C, Gibson-Corley KN, Hammond DL. Pain. 2020;161(10):2364-2375. doi:10.1097/j.pain.0000000000001924.
Nicotinamide Riboside Opposes Type 2 Diabetes and Neuropathy in Mice. Trammell SA, Weidemann BJ, Chadda A, et al. Scientific Reports. 2016;6:26933. doi:10.1038/srep26933.
Nicotinamide Riboside, a Form of Vitamin B3 and NAD+ Precursor, Relieves the Nociceptive and Aversive Dimensions of Paclitaxel-Induced Peripheral Neuropathy in Female Rats. Hamity MV, White SR, Walder RY, et al. Pain. 2017;158(5):962-972. doi:10.1097/j.pain.0000000000000862.
Restoration of Mitochondrial Function Alleviates Trigeminal Neuropathic Pain in Mice. Yang J, Xie S, Guo J, et al. Free Radical Biology & Medicine. 2025;226:185-198. doi:10.1016/j.freeradbiomed.2024.11.011.
Preclinical and Clinical Evidence of NAD Precursors in Health, Disease, and Ageing. Reiten OK, Wilvang MA, Mitchell SJ, Hu Z, Fang EF. Mechanisms of Ageing and Development. 2021;199:111567. doi:10.1016/j.mad.2021.111567.
NAD+ Precursors in Human Health and Disease: Current Status and Future Prospects. Yaku K, Nakagawa T. Antioxidants & Redox Signaling. 2023;39(16-18):1133-1149. doi:10.1089/ars.2023.0354.
Vitamin D for the Treatment of Chronic Painful Conditions in Adults. Straube S, Derry S, Straube C, Moore RA. The Cochrane Database of Systematic Reviews. 2015;(5):CD007771. doi:10.1002/14651858.CD007771.pub3.
The Effect of Vitamin D Supplementation on Pain: An Analysis of Data From the D-Health Randomised Controlled Trial. Rahman A, Waterhouse M, Baxter C, et al. The British Journal of Nutrition. 2023;130(4):633-640. doi:10.1017/S0007114522003567.
Effect of Vitamin D Supplementation on Pain: A Systematic Review and Meta-Analysis. Wu Z, Malihi Z, Stewart AW, Lawes CM, Scragg R. Pain Physician. 2016 Sep-Oct;19(7):415-27.
Monthly Vitamin D Supplementation, Pain, and Pattern of Analgesic Prescription: Secondary Analysis From the Randomized, Double-Blind, Placebo-Controlled Vitamin D Assessment Study. Wu Z, Camargo CA, Malihi Z, et al. Pain. 2018;159(6):1074-1082. doi:10.1097/j.pain.0000000000001189.
Effect of Vitamin D Supplementation in Chronic Widespread Pain: A Systematic Review and Meta-Analysis. Yong WC, Sanguankeo A, Upala S. Clinical Rheumatology. 2017;36(12):2825-2833. doi:10.1007/s10067-017-3754-y.
Cholecalciferol (Vitamin D) Reduces Rat Neuropathic Pain by Modulating Opioid Signaling. Poisbeau P, Aouad M, Gazzo G, et al. Molecular Neurobiology. 2019;56(10):7208-7221. doi:10.1007/s12035-019-1582-6.
Analgesic Efficacy of Melatonin: A Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled Trials. Oh SN, Myung SK, Jho HJ. Journal of Clinical Medicine. 2020;9(5):E1553. doi:10.3390/jcm9051553.
Analgesic Benefits of Pharmacological and Nonpharmacological Sleep Interventions for Adults With Fibromyalgia: A Systematic Review and Meta-Analyses. Abolhosseini S, Malatesta A, Asmundson AJN, Gilron I, Salomons TV. Pain. 2025;:00006396-990000000-00967. doi:10.1097/j.pain.0000000000003708.
Exogenous Melatonin in the Treatment of Pain: A Systematic Review and Meta-Analysis. Zhu C, Xu Y, Duan Y, et al. Oncotarget. 2017;8(59):100582-100592. doi:10.18632/oncotarget.21504.
Analgesic Effects of Melatonin: A Review of Current Evidence From Experimental and Clinical Studies. Wilhelmsen M, Amirian I, Reiter RJ, Rosenberg J, Gögenur I. Journal of Pineal Research. 2011;51(3):270-7. doi:10.1111/j.1600-079X.2011.00895.x.
Melatonin Treatment Has Consistent but Transient Beneficial Effects on Sleep Measures and Pain in Patients With Severe Chronic Pain: The DREAM-CP Randomised Controlled Trial. Onyeakazi UM, Columb MO, Rosalind A, Kanakarajan S, Galley HF. British Journal of Anaesthesia. 2024;132(4):725-734. doi:10.1016/j.bja.2024.01.012.
Adjuvant Use of Melatonin for Treatment of Fibromyalgia. Hussain SA, Al-Khalifa II, Jasim NA, Gorial FI. Journal of Pineal Research. 2011;50(3):267-71. doi:10.1111/j.1600-079X.2010.00836.x.
Emerging Promise of Sulforaphane-Mediated Nrf2 Signaling Cascade Against Neurological Disorders. Uddin MS, Mamun AA, Jakaria M, et al. The Science of the Total Environment. 2020;707:135624. doi:10.1016/j.scitotenv.2019.135624.
Treatment With Sulforaphane Produces Antinociception and Improves Morphine Effects During Inflammatory Pain in Mice. Redondo A, Chamorro PAF, Riego G, Leánez S, Pol O. The Journal of Pharmacology and Experimental Therapeutics. 2017;363(3):293-302. doi:10.1124/jpet.117.244376.
Sulforaphane: An Emerging Star in Neuroprotection and Neurological Disease Prevention. Wu N, Luo Z, Deng R, et al. Biochemical Pharmacology. 2025;233:116797. doi:10.1016/j.bcp.2025.116797.
Effects of Sulforaphane in the Central Nervous System. Huang C, Wu J, Chen D, et al. European Journal of Pharmacology. 2019;853:153-168. doi:10.1016/j.ejphar.2019.03.010.
Broccoli for the Brain: A Review of the Neuroprotective Mechanisms of Sulforaphane. Bessetti RN, Litwa KA. Frontiers in Cellular Neuroscience. 2025;19:1601366. doi:10.3389/fncel.2025.1601366.
Sulforaphane-Enriched Broccoli Sprouts Pretreated by Pulsed Electric Fields Reduces Neuroinflammation and Ameliorates Scopolamine-Induced Amnesia in Mouse Brain Through Its Antioxidant Ability via Nrf2-Ho-1 Activation. Subedi L, Cho K, Park YU, Choi HJ, Kim SY. Oxidative Medicine and Cellular Longevity. 2019;2019:3549274. doi:10.1155/2019/3549274.
The Emerging Role of Quercetin in the Treatment of Chronic Pain. Liu C, Liu DQ, Tian YK, et al. Current Neuropharmacology. 2022;20(12):2346-2353. doi:10.2174/1570159X20666220812122437.
Quercetin Alleviates Osteoarthritis Pain by Inhibiting Vascular Endothelial Growth Factor a Through Regulating cGAS/STING Pathway. Hu E, Wei Y, Liao T, et al. Journal of Cellular and Molecular Medicine. 2026;30(1):e70992. doi:10.1111/jcmm.70992.
Advance in the Pharmacological Effects of Quercetin in Modulating Oxidative Stress and Inflammation Related Disorders. Zhou Y, Qian C, Tang Y, et al. Phytotherapy Research : PTR. 2023;37(11):4999-5016. doi:10.1002/ptr.7966.
Quercetin Alleviates Rat Osteoarthritis by Inhibiting Inflammation and Apoptosis of Chondrocytes, Modulating Synovial Macrophages Polarization to M2 Macrophages. Hu Y, Gui Z, Zhou Y, et al. Free Radical Biology & Medicine. 2019;145:146-160. doi:10.1016/j.freeradbiomed.2019.09.024.
Quercetin-Mediated SIRT1 Activation Attenuates Collagen-Induced Mice Arthritis. Shen P, Lin W, Ba X, et al. Journal of Ethnopharmacology. 2021;279:114213. doi:10.1016/j.jep.2021.114213.
Molecular Docking of Quercetin: A Promising Approach for the Development of New Anti-Inflammatory and Analgesic Drugs. Ettitaou A, Kabdy H, Oubella K, et al. Natural Product Research. 2025;39(11):3202-3211. doi:10.1080/14786419.2024.2333053.
Comparative Investigation of Analgesic Tolerance to Taurine, Sodium Salicylate and Morphine: Involvement of Peripheral Muscarinic Receptors. Akbari E, Beheshti F, Zarmehri HA, et al. Neuroscience Letters. 2023;795:137041. doi:10.1016/j.neulet.2022.137041.
Taurine Protects Against Myelin Damage of Sciatic Nerve in Diabetic Peripheral Neuropathy Rats by Controlling Apoptosis of Schwann Cells via NGF/Akt/GSK3β Pathway. Li K, Shi X, Luo M, et al. Experimental Cell Research. 2019;383(2):111557. doi:10.1016/j.yexcr.2019.111557.
Taurine Ameliorates Axonal Damage in Sciatic Nerve of Diabetic Rats and High Glucose Exposed DRG Neuron by PI3K/Akt/mTOR-dependent Pathway. Zhang M, Shi X, Luo M, et al. Amino Acids. 2021;53(3):395-406. doi:10.1007/s00726-021-02957-1.
Antinociceptive Effect of Intrathecal Administration of Taurine in Rat Models of Neuropathic Pain. Terada T, Hara K, Haranishi Y, Sata T. Canadian Journal of Anaesthesia = Journal Canadien d’Anesthesie. 2011;58(7):630-637. doi:10.1007/s12630-011-9504-8.
Taurine Replacement Attenuates Hyperalgesia and Abnormal Calcium Signaling in Sensory Neurons of STZ-D Rats. Li F, Obrosova IG, Abatan O, et al. American Journal of Physiology. Endocrinology and Metabolism. 2005;288(1):E29-36. doi:10.1152/ajpendo.00168.2004.
Neuropsychopharmacological Actions of Taurine. Banerjee SP, Ragnauth A, Chan CY, et al. Advances in Experimental Medicine and Biology. 2013;775:3-18. doi:10.1007/978-1-4614-6130-2_1.

Emphasis on Education

Accurate Clinic promotes patient education as the foundation of it’s medical care. In Dr. Ehlenberger’s integrative approach to patient care, including conventional and complementary and alternative medical (CAM) treatments, he may encourage or provide advice about the use of supplements. However, the specifics of choice of supplement, dosing and duration of treatment should be individualized through discussion with Dr. Ehlenberger. The following information and reference articles are presented to provide the reader with some of the latest research to facilitate evidence-based, informed decisions regarding the use of conventional as well as CAM treatments.

For medical-legal reasons, access to these links is limited to patients enrolled in an Accurate Clinic medical program.

Should you wish more information regarding any of the subjects listed – or not listed – here, please contact Dr. Ehlenberger. He has literally thousands of published articles to share on hundreds of topics associated with pain management, weight loss, nutrition, addiction recovery and emergency medicine. It would take years for you to read them, as it did him.

For more information, please contact Accurate Clinic.

Supplements recommended by Dr. Ehlenberger may be purchased commercially online

Please read about our statement regarding the sale of products recommended by Dr. Ehlenberger.

Accurate Education – Nutraceuticals to Reduce the Driving Forces of Chronic Pain (Part 2)

Nutraceuticals:

Nutraceuticals to Reduce the Driving Forces of Chronic Pain (Part 2)

Key to Links:

On this page:

PART 2 (#11-16)

Nutraceuticals to Reduce the Driving Forces of Chronic Pain:

Part 2 – Nutraceuticals 11-16 and Summary

11. NAD+ PRECURSORS (Nicotinamide Riboside/NMN)

12. VITAMIN D3 (Cholecalciferol)

13. MELATONIN

14. SULFORAPHANE

15. QUERCETIN

16. TAURINE

SUMMARY AND CLINICAL INTEGRATION

Evidence Hierarchy for Chronic Pain Nutraceuticals

References

Suggested Combination Protocols by Pain Type

Neuropathic Pain:

Inflammatory/Osteoarthritis Pain:

Fibromyalgia/Central Sensitization:

Migraine Prophylaxis:

Chemotherapy-Induced Neuropathy:

General Principles for Clinical Integration

Emphasis on Education

For more information, please contact Accurate Clinic.